Kynam Capital Management and related reporting persons filed an amended Schedule 13G/A disclosing a passive ownership stake in Viridian Therapeutics, Inc. As of 12/31/2025, they collectively reported beneficial ownership of 1,470,541 shares of Viridian common stock, representing 1.54% of the outstanding class.
The filing shows Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang each having shared voting and shared dispositive power over these 1,470,541 shares, with no sole voting or dispositive power. The certification states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Viridian.
Positive
None.
Negative
None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Viridian Therapeutics (VRDN) does Kynam Capital report in this Schedule 13G/A?
Kynam Capital and related filers report beneficial ownership of 1,470,541 Viridian shares, or 1.54% of the common stock. This reflects a relatively small, passive position rather than a controlling stake in the company’s equity.
Which entities are the reporting persons in the Viridian Therapeutics (VRDN) Schedule 13G/A?
The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. All three report the same 1,470,541 Viridian shares with shared voting and dispositive power, and no sole authority over the shares.
Does the Kynam Capital Schedule 13G/A indicate an activist intent toward Viridian Therapeutics (VRDN)?
The filing expressly describes the holdings as acquired and held in the ordinary course of business. It states they are not held to change or influence control of Viridian, indicating a passive investment rather than an activist position.
What voting and dispositive powers over Viridian (VRDN) shares are reported by Kynam Capital?
Kynam Capital Management, LP, its GP, and Yue Tang each report zero sole voting and sole dispositive power. They each report shared voting power and shared dispositive power over 1,470,541 Viridian common shares, matching their reported beneficial ownership.
As of what date is Kynam Capital’s Viridian Therapeutics (VRDN) ownership reported?
The ownership information is reported as of 12/31/2025, the date of the event requiring the filing. That date anchors the 1,470,541 Viridian shares and 1.54% beneficial ownership disclosed in this amended Schedule 13G/A.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Viridian Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
92790C104
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
92790C104
1
Names of Reporting Persons
Kynam Capital Management, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,470,541.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,470,541.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,470,541.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.54 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP No.
92790C104
1
Names of Reporting Persons
Kynam Capital Management GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,470,541.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,470,541.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,470,541.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.54 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
92790C104
1
Names of Reporting Persons
Yue Tang
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,470,541.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,470,541.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,470,541.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.54 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Viridian Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
221 Crescent Street, Suite 103A, Waltham, MASSACHUSETTS
02453
Item 2.
(a)
Name of person filing:
Kynam Capital Management, LP
Kynam Capital Management GP, LLC
Yue Tang
(b)
Address or principal business office or, if none, residence:
221 ELM ROAD
PRINCETON, New Jersey
08540
(c)
Citizenship:
Kynam Capital Management, LP - DELAWARE
Kynam Capital Management GP, LLC - DELAWARE
Yue Tang - UNITED STATES
(d)
Title of class of securities:
Common Stock, $0.01 par value
(e)
CUSIP No.:
92790C104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1,470,541
(b)
Percent of class:
1.54 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(ii) Shared power to vote or to direct the vote:
Kynam Capital Management, LP - 1,470,541
Kynam Capital Management GP, LLC - 1,470,541
Yue Tang - 1,470,541
(iii) Sole power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(iv) Shared power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 1,470,541
Kynam Capital Management GP, LLC - 1,470,541
Yue Tang - 1,470,541
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
